The Immunomonitoring lab (E.M. Inderberg) analyses the immune cell status of the innate or adaptive immune system with a specific expertise on characterization of T-cell responses. More specific immunomonitoring techniques are developed depending on the requirements in each clinical study. The analysis of the immune response against cancer vaccines/tumour antigens in blood samples from these patients before and after treatment allows a better understanding of 1) the underlying mechanisms of action of the immunotherapy 2) the prognostic value of immunological parameters and 3) the use of new knowledge about immune parameters to design improved immunotherapy treatments.
The first stage in immunomonitoring is freezing of the lymphocytes and tumour samples from clinical studies.
The patient samples are then tested for antigen specific immune responses in more detailed immunomonitoring. This includes tests such as:
- Proliferation test following tumour peptide presentation, or recall antigens.
- IFN-γ ELISPOT testing (or other cytokines) done ex vivo on PBMC or immune cell subsets CD4+ or CD8+ T cells
- Measurement of cytokine production by luminex or ELISA after specific stimulation or exposure to antigens.
- Measuring the frequency of antigen-specific T cells using HLA multimers
-Intracellular cytokine staining by flow cytometry
- Biomarker studies
Further research includes methods such as T cells cloning by limiting dilution, cytotoxicity assays and phenotyping
The Immunomonitoring group participates in The European Association for Cancer Immunotherapy (CIMT) Immunoguidance panels (CIP) since 2008 and also the US Cancer Immunotherapy Consortium (CIC) proficiency panels to ensure an external validation of assay performance and to enhance assay harmonization.
Ongoing projects/clinical trials:
- Pre-clinical development and clinical testing of candidate vaccines based on long-peptide corresponding to specific tumour antigens with immunological adjuvants
- DC005 Prostate cancer
- DC vaccination Glioblastoma
- CD-FDC-001 study in AML patients (Medigene GmbH)
- IPI4, Ipilimumab phase IV study
- BGBIL006 (Haukeland Universitetssykehus HF)
- UV1/hTERT-P (Prostate cancer), UV1/hTERT-L (Lung cancer) (Ultimovacs AS)
- TG001, TG002 (Targovax AS)
- LTX-315 (Lytix Biopharma AS)
- PCIA202-12 (PCI Biotech AS)